miR-124 and VAMP3 Act Antagonistically in Human Neuroblastoma.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
04 Oct 2023
Historique:
received: 05 09 2023
revised: 25 09 2023
accepted: 02 10 2023
medline: 1 11 2023
pubmed: 14 10 2023
entrez: 14 10 2023
Statut: epublish

Résumé

Neuroblastoma (NB) is the most common extracranial solid tumor that affects developing nerve cells in the fetus, infants, and children. miR-124 is a microRNA (miRNA) enriched in neuronal tissues, and VAMP3 (vesicle-associated membrane protein 3) has been reported to be an miR-124 target, although the relationship between NB and miR-124 or VAMP3 is unknown. Our current work identified that miR-124 levels are high in NB cases and that elevated miR-124 correlates with worse NB outcomes. Conversely, depressed VAMP3 correlates with worse NB outcomes. To investigate the mechanisms by which miR-124 and VAMP3 regulate NB, we altered miR-124 or VAMP3 expression in human NB cells and observed that increased miR-124 and reduced VAMP3 stimulated cell proliferation and suppressed apoptosis, while increased VAMP3 had the opposite effects. Genome-wide mRNA expression analyses identified gene and pathway changes which might explain the NB cell phenotypes. Together, our studies suggest that miR-124 and VAMP3 could be potential new markers of NB and targets of NB treatments.

Identifiants

pubmed: 37834325
pii: ijms241914877
doi: 10.3390/ijms241914877
pmc: PMC10573497
pii:
doi:

Substances chimiques

Vesicle-Associated Membrane Protein 3 0
MicroRNAs 0
VAMP3 protein, human 0
MIRN124 microRNA, human 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Références

Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11691-6
pubmed: 9751727
J Biol Chem. 2012 Oct 26;287(44):37530-9
pubmed: 22936810
Nat Biotechnol. 2014 Sep;32(9):903-14
pubmed: 25150838
Front Oncol. 2022 Feb 04;12:829045
pubmed: 35186763
Clin Genet. 2010 Apr;77(4):306-13
pubmed: 20132241
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50
pubmed: 16199517
J Cell Sci. 2012 Aug 15;125(Pt 16):3827-39
pubmed: 22573826
Mol Cancer. 2010 Oct 15;9:277
pubmed: 20950435
FEBS Lett. 2011 Nov 16;585(22):3582-6
pubmed: 22024478
Biomedicines. 2021 Jan 19;9(1):
pubmed: 33478086
J Cell Biol. 2000 May 1;149(3):697-706
pubmed: 10791982
Cancer Med. 2019 Sep;8(12):5638-5650
pubmed: 31389160
J Biosci. 2017 Dec;42(4):555-563
pubmed: 29229874
Cell Mol Neurobiol. 2022 Oct;42(7):2031-2053
pubmed: 33886036
Comput Math Methods Med. 2022 May 4;2022:7525048
pubmed: 35572821
Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9779-84
pubmed: 12902540
Mol Cell. 2014 Oct 2;56(1):104-15
pubmed: 25263593
Cancer Res. 2005 Apr 15;65(8):3136-45
pubmed: 15833843
Curr Oncol Rep. 2022 Aug;24(8):1053-1062
pubmed: 35362827
Biochim Biophys Acta Gene Regul Mech. 2017 Dec;1860(12):1179-1188
pubmed: 29109067
J Clin Oncol. 2009 Jan 10;27(2):298-303
pubmed: 19047290
Signal Transduct Target Ther. 2019 Aug 16;4:27
pubmed: 31637007
Nature. 1993 Jul 22;364(6435):346-9
pubmed: 8332193
Cancer Metastasis Rev. 2020 Mar;39(1):275-285
pubmed: 31927719
Nat Commun. 2015 Apr 21;6:6919
pubmed: 25897521
Mol Cell Biol. 2001 Mar;21(5):1573-80
pubmed: 11238894
Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9559-64
pubmed: 8790369
Dis Model Mech. 2021 Apr 1;14(4):
pubmed: 33973623
Curr Opin Genet Dev. 2011 Aug;21(4):511-7
pubmed: 21530229
Cell. 2018 Mar 22;173(1):20-51
pubmed: 29570994
Oncogene. 2004 Aug 5;23(35):5912-22
pubmed: 15195138
Oncogene. 2022 Jan;41(5):622-633
pubmed: 34789839
J Invest Dermatol. 2019 Nov;139(11):2324-2333
pubmed: 31128202
Front Cell Dev Biol. 2020 Nov 20;8:559553
pubmed: 33330445
Nature. 2012 Feb 22;483(7391):589-93
pubmed: 22367537
Cancer Lett. 2014 Dec 28;355(2):210-6
pubmed: 25264923
Cells. 2019 Jul 30;8(8):
pubmed: 31366019
Trends Genet. 2022 Apr;38(4):379-394
pubmed: 34728089
Cell Death Dis. 2013 Apr 11;4:e586
pubmed: 23579273
Mol Cancer Res. 2020 Jan;18(1):68-78
pubmed: 31624087
BMC Cancer. 2014 May 02;14:309
pubmed: 24885481
Cell Tissue Res. 2018 May;372(2):211-221
pubmed: 29445860
J Clin Oncol. 2000 May;18(9):1888-99
pubmed: 10784629

Auteurs

Xiaoxiao Zhang (X)

Department of Zoology, College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, China.

Chengyong Yang (C)

Department of Zoology, College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, China.

Zhen Meng (Z)

Department of Zoology, College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, China.

Huanhuan Zhong (H)

Department of Zoology, College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, China.

Xutian Hou (X)

Department of Zoology, College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, China.

Fenfen Wang (F)

Department of Zoology, College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, China.

Yiping Lu (Y)

Department of Zoology, College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, China.

Jingjing Guo (J)

Centre in Artificial Intelligence Driven Drug Discovery, Faculty of Applied Sciences, Macao Polytechnic University, Macao 999078, China.

Yan Zeng (Y)

Department of Zoology, College of Life Sciences, Nanjing Agricultural University, Nanjing 210095, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH